Khloé Kardashian has given an unusually detailed accounting of the cosmetic procedures she has undergone, posting the information in response to a London aesthetics doctor who publicly speculated about her appearance. In a 28 June Instagram comment, the 41-year-old reality-TV personality welcomed the doctor’s analysis as a "great compliment" and then itemised what she described as the complete list of work she has had so far.

Read more

AbbVie said Monday it has struck a definitive agreement to buy Capstan Therapeutics in a cash transaction worth up to $2.1 billion, strengthening the drugmaker’s immunology portfolio with early-stage cell-therapy programs. The acquisition, which is subject to customary regulatory approvals, will be funded entirely in cash at closing, the companies said.

San Diego-based Capstan is developing in vivo chimeric antigen receptor T-cell (CAR-T) therapies that aim to reprogram a patient’s immune cells directly inside the body. Its lead candidate, CPTX2309, uses a targeted lipid nanoparticle to deliver mRNA encoding an anti-CD19 CAR to cytotoxic T cells and is in Phase 1 testing for B-cell-mediated autoimmune diseases. Capstan, launched in 2022 and backed by roughly $340 million in venture funding, also brings AbbVie a proprietary tLNP platform that could broaden applications of the technology to fibrosis and cancer.

The deal underscores AbbVie’s drive to replenish revenue lost after arthritis blockbuster Humira faced biosimilar competition last year and highlights escalating large-pharma interest in next-generation, off-the-shelf cell therapies that could offer broader patient access than traditional ex vivo CAR-T treatments.

AbbVie announced new data from a Phase 3 head-to-head study demonstrating that its migraine drug Atogepant (marketed as QULIPTA® / AQUIPTA®) achieved superiority across all endpoints compared to the widely used generic treatment topiramate for migraine prevention. The study met its primary goal, confirming Atogepant's efficacy in reducing migraine frequency. Meanwhile, Axsome Therapeutics is set to present data related to its SYMBRAVO® (meloxicam and rizatriptan) clinical program at the 67th Annual Scientific Meeting of the American Headache Society (AHS). Pfizer also highlighted its commitment to migraine care at the same meeting, presenting 14 abstracts covering diverse patient populations, including those unsuitable for triptan use and those experiencing multiple migraine attacks monthly. Additionally, recent research indicates that GLP-1 agonists, such as Ozempic, are associated with significantly reduced migraine frequency, particularly in obese participants.

Health authorities have issued warnings following multiple adverse reactions linked to cosmetic procedures at an unlicensed spa in Milton. Fourteen cases of botulism have been reported, with patients experiencing symptoms including eye drooping. The incidents have raised concerns about the safety of Botox treatments and 'vampire facial' clinics, which have also been flagged for potential HIV risks. Several individuals in County Durham have been treated for suspected botulism after undergoing cosmetic procedures, prompting a health alert to caution the public about the dangers associated with unregulated cosmetic treatments.

Health authorities in Massachusetts are investigating a cluster of at least 12 suspected botulism cases linked to Botox injections at a medical spa in Milton. The Massachusetts Department of Public Health is leading the inquiry following reports of illness connected to the spa. The facility, reportedly owned by a Brazilian, has drawn attention after multiple patients exhibited symptoms consistent with botulism, a rare but serious condition caused by bacterial toxin exposure. Medical experts emphasize the risks associated with cosmetic procedures performed outside of board-certified dermatologists, underscoring the importance of professional oversight in such treatments. The investigation is ongoing as officials work to determine the source of contamination and prevent further cases.

Jennifer Garner has shared her perspective on aging and cosmetic treatments, revealing that she does not use Botox because it 'doesn’t work very well' for her. Instead of opting for injectables, Garner prefers alternative approaches to maintaining her appearance, such as styling choices like bangs. She expressed a relaxed attitude toward aging and is not concerned about it, emphasizing a natural acceptance rather than relying on cosmetic procedures.

Plastic surgeon Dr. Steven Levine has been identified as the professional responsible for Kris Jenner's notably rejuvenated appearance. Recent public photos, including one of Jenner holding a baguette in Paris, have highlighted her dramatically refreshed look. Commentators have remarked that Jenner's transformation not only reverses the signs of aging but has altered her visage to closely resemble that of her daughter, Kim Kardashian. Media coverage has described this change as a remarkable rejuvenation, with some observers noting the striking similarity between Jenner and Kardashian following the cosmetic procedures.

AbbVie Inc. reported its first-quarter 2025 financial results with adjusted earnings per share (EPS) of $2.46, surpassing the consensus estimate of approximately $2.38. The company's net revenue reached $13.34 billion, exceeding expectations of around $12.92 billion. Key product revenues included Skyrizi at $3.43 billion, beating the estimated $3.2 billion, Rinvoq at $1.72 billion versus an estimate of $1.58 billion, and Humira at $1.12 billion, which fell short of the $1.32 billion estimate.

On a GAAP basis, AbbVie reported diluted EPS of $0.72, a decline of 6.5%, while adjusted diluted EPS increased by 6.5%. The results included an unfavorable impact of $0.13 per share related to acquired in-process research and development (IPR&D) and milestone expenses. For the full year 2025, AbbVie projects adjusted EPS in the range of $12.09 to $12.29, an upward revision from the prior guidance of $11.99 to $12.19. The company noted that its forecast does not reflect any potential trade policy shifts and is based on existing conditions.

Democratic Congresswoman Jasmine Crockett from Texas is facing scrutiny for reportedly accepting approximately $400,000 from Political Action Committees (PACs) while previously denying such contributions. Records indicate that she received $370,000 specifically from PACs, alongside business trips to Qatar, which has been criticized for its support of Hamas. Crockett's donor list includes major corporations such as pharmaceutical companies AbbVie and Gilead Sciences, financial services firms BlackRock and Goldman Sachs, as well as defense contractors Lockheed Martin and RTX. Other notable brands in her donor network include McDonald's, Home Depot, CVS, Verizon, and Toyota.

The use of Botox, a cosmetic treatment that paralyzes nerves and muscles to reduce fine lines and wrinkles, has surged among young women, particularly those aged 18 to 24. Between 2019 and 2022, the application of botulinum toxin increased by 71% among patients aged 20 to 29 and by 75% among those 19 years old and younger. This trend has raised concerns among health care specialists, particularly naturopaths, regarding the implications of Botox use by individuals without visible wrinkles. Some young women are opting for 'baby Botox,' which involves smaller doses aimed at maintaining smooth skin. Experts emphasize that Botox injections should only be performed by licensed professionals, such as dermatologists or plastic surgeons, to mitigate risks associated with misuse or mishandling. While the likelihood of fatal overdose is minimal, complications can arise from improper administration.

AbbVie and Johnson & Johnson have announced a collaboration with Apheris to enhance AI-driven drug discovery. This partnership aims to integrate proprietary data from both pharmaceutical companies to refine the OpenFold3 protein model in a secure environment, preserving confidentiality. The collaboration is expected to illuminate complex chemical interactions and improve the efficiency of drug discovery processes. Apheris will facilitate the pooling of data while ensuring privacy, which is crucial for advancing AI capabilities in the pharmaceutical sector. The initiative reflects a growing trend of leveraging artificial intelligence to accelerate drug development and improve healthcare outcomes.

Khloé Kardashian has given an unusually detailed accounting of the cosmetic procedures she has undergone, posting the information in response to a London aesthetics doctor who publicly speculated about her appearance. In a 28 June Instagram comment, the 41-year-old reality-TV personality welcomed the doctor’s analysis as a "great compliment" and then itemised what she described as the complete list of work she has had so far.

Read more

AbbVie said Monday it has struck a definitive agreement to buy Capstan Therapeutics in a cash transaction worth up to $2.1 billion, strengthening the drugmaker’s immunology portfolio with early-stage cell-therapy programs. The acquisition, which is subject to customary regulatory approvals, will be funded entirely in cash at closing, the companies said.

San Diego-based Capstan is developing in vivo chimeric antigen receptor T-cell (CAR-T) therapies that aim to reprogram a patient’s immune cells directly inside the body. Its lead candidate, CPTX2309, uses a targeted lipid nanoparticle to deliver mRNA encoding an anti-CD19 CAR to cytotoxic T cells and is in Phase 1 testing for B-cell-mediated autoimmune diseases. Capstan, launched in 2022 and backed by roughly $340 million in venture funding, also brings AbbVie a proprietary tLNP platform that could broaden applications of the technology to fibrosis and cancer.

The deal underscores AbbVie’s drive to replenish revenue lost after arthritis blockbuster Humira faced biosimilar competition last year and highlights escalating large-pharma interest in next-generation, off-the-shelf cell therapies that could offer broader patient access than traditional ex vivo CAR-T treatments.

AbbVie announced new data from a Phase 3 head-to-head study demonstrating that its migraine drug Atogepant (marketed as QULIPTA® / AQUIPTA®) achieved superiority across all endpoints compared to the widely used generic treatment topiramate for migraine prevention. The study met its primary goal, confirming Atogepant's efficacy in reducing migraine frequency. Meanwhile, Axsome Therapeutics is set to present data related to its SYMBRAVO® (meloxicam and rizatriptan) clinical program at the 67th Annual Scientific Meeting of the American Headache Society (AHS). Pfizer also highlighted its commitment to migraine care at the same meeting, presenting 14 abstracts covering diverse patient populations, including those unsuitable for triptan use and those experiencing multiple migraine attacks monthly. Additionally, recent research indicates that GLP-1 agonists, such as Ozempic, are associated with significantly reduced migraine frequency, particularly in obese participants.

Health authorities have issued warnings following multiple adverse reactions linked to cosmetic procedures at an unlicensed spa in Milton. Fourteen cases of botulism have been reported, with patients experiencing symptoms including eye drooping. The incidents have raised concerns about the safety of Botox treatments and 'vampire facial' clinics, which have also been flagged for potential HIV risks. Several individuals in County Durham have been treated for suspected botulism after undergoing cosmetic procedures, prompting a health alert to caution the public about the dangers associated with unregulated cosmetic treatments.

Health authorities in Massachusetts are investigating a cluster of at least 12 suspected botulism cases linked to Botox injections at a medical spa in Milton. The Massachusetts Department of Public Health is leading the inquiry following reports of illness connected to the spa. The facility, reportedly owned by a Brazilian, has drawn attention after multiple patients exhibited symptoms consistent with botulism, a rare but serious condition caused by bacterial toxin exposure. Medical experts emphasize the risks associated with cosmetic procedures performed outside of board-certified dermatologists, underscoring the importance of professional oversight in such treatments. The investigation is ongoing as officials work to determine the source of contamination and prevent further cases.

Jennifer Garner has shared her perspective on aging and cosmetic treatments, revealing that she does not use Botox because it 'doesn’t work very well' for her. Instead of opting for injectables, Garner prefers alternative approaches to maintaining her appearance, such as styling choices like bangs. She expressed a relaxed attitude toward aging and is not concerned about it, emphasizing a natural acceptance rather than relying on cosmetic procedures.

Plastic surgeon Dr. Steven Levine has been identified as the professional responsible for Kris Jenner's notably rejuvenated appearance. Recent public photos, including one of Jenner holding a baguette in Paris, have highlighted her dramatically refreshed look. Commentators have remarked that Jenner's transformation not only reverses the signs of aging but has altered her visage to closely resemble that of her daughter, Kim Kardashian. Media coverage has described this change as a remarkable rejuvenation, with some observers noting the striking similarity between Jenner and Kardashian following the cosmetic procedures.

AbbVie Inc. reported its first-quarter 2025 financial results with adjusted earnings per share (EPS) of $2.46, surpassing the consensus estimate of approximately $2.38. The company's net revenue reached $13.34 billion, exceeding expectations of around $12.92 billion. Key product revenues included Skyrizi at $3.43 billion, beating the estimated $3.2 billion, Rinvoq at $1.72 billion versus an estimate of $1.58 billion, and Humira at $1.12 billion, which fell short of the $1.32 billion estimate.

On a GAAP basis, AbbVie reported diluted EPS of $0.72, a decline of 6.5%, while adjusted diluted EPS increased by 6.5%. The results included an unfavorable impact of $0.13 per share related to acquired in-process research and development (IPR&D) and milestone expenses. For the full year 2025, AbbVie projects adjusted EPS in the range of $12.09 to $12.29, an upward revision from the prior guidance of $11.99 to $12.19. The company noted that its forecast does not reflect any potential trade policy shifts and is based on existing conditions.

Democratic Congresswoman Jasmine Crockett from Texas is facing scrutiny for reportedly accepting approximately $400,000 from Political Action Committees (PACs) while previously denying such contributions. Records indicate that she received $370,000 specifically from PACs, alongside business trips to Qatar, which has been criticized for its support of Hamas. Crockett's donor list includes major corporations such as pharmaceutical companies AbbVie and Gilead Sciences, financial services firms BlackRock and Goldman Sachs, as well as defense contractors Lockheed Martin and RTX. Other notable brands in her donor network include McDonald's, Home Depot, CVS, Verizon, and Toyota.

The use of Botox, a cosmetic treatment that paralyzes nerves and muscles to reduce fine lines and wrinkles, has surged among young women, particularly those aged 18 to 24. Between 2019 and 2022, the application of botulinum toxin increased by 71% among patients aged 20 to 29 and by 75% among those 19 years old and younger. This trend has raised concerns among health care specialists, particularly naturopaths, regarding the implications of Botox use by individuals without visible wrinkles. Some young women are opting for 'baby Botox,' which involves smaller doses aimed at maintaining smooth skin. Experts emphasize that Botox injections should only be performed by licensed professionals, such as dermatologists or plastic surgeons, to mitigate risks associated with misuse or mishandling. While the likelihood of fatal overdose is minimal, complications can arise from improper administration.

AbbVie and Johnson & Johnson have announced a collaboration with Apheris to enhance AI-driven drug discovery. This partnership aims to integrate proprietary data from both pharmaceutical companies to refine the OpenFold3 protein model in a secure environment, preserving confidentiality. The collaboration is expected to illuminate complex chemical interactions and improve the efficiency of drug discovery processes. Apheris will facilitate the pooling of data while ensuring privacy, which is crucial for advancing AI capabilities in the pharmaceutical sector. The initiative reflects a growing trend of leveraging artificial intelligence to accelerate drug development and improve healthcare outcomes.